Publications
Publications
Show Results For
- All HBS Web
(5,728)
- Faculty Publications (682)
- June 2015
- Supplement
Generating Higher Value at IBM (A): EPS Forecasting Model
By: Benjamin C. Esty and Scott Mayfield
This case analyzes IBM's financial performance and its capital allocation decisions over a 10-year period from 2004-2013, during which IBM returned more than $140B to shareholders through a combination of dividends and share repurchases. During this time, CEO Sam... View Details
- June 2015 (Revised September 2017)
- Supplement
Generating Higher Value at IBM
By: Benjamin C. Esty and Scott Mayfield
This case analyzes IBM's financial performance and its capital allocation decisions over a 10-year period from 2004-2013, during which IBM returned more than $140B to shareholders through a combination of dividends and share repurchases. During this time, CEO Sam... View Details
- 2015
- Working Paper
Customers and Investors: A Framework for Understanding Financial Institutions
By: Robert C. Merton and Robert T. Thakor
Financial institutions have both investors and customers. Investors, such as those who invest in stocks and bonds or private/public-sector guarantors of institutions, expect an appropriate risk-adjusted return in exchange for the financing and risk-bearing that they... View Details
Keywords: Financial Institutions
- Summer 2015
- Article
Investment Incentives in Open-Source and Proprietary Two-Sided Platforms
By: Ramon Casadesus-Masanell and Gaston Llanes
We study incentives to invest in platform quality in open-source and proprietary two-sided platforms. Open platforms have open access, and developers invest to improve the platform. Proprietary platforms have closed access, and investment is done by the platform owner.... View Details
- May 2015 (Revised September 2015)
- Case
Philips Healthcare: Marketing the HealthSuite Digital Platform
By: John A. Quelch and Margaret L. Rodriguez
In June 2014, leading healthcare and consumer technology company, Royal Philips ("Philips"), announced its HealthSuite Digital Platform to house healthcare data and enable applications used by physicians and patients. Philips had strong equity in the healthcare... View Details
- May 2015 (Revised September 2017)
- Case
Generating Higher Value at IBM (A)
By: Benjamin C. Esty and E. Scott Mayfield
This case analyzes IBM's financial performance and its capital allocation decisions over a 10-year period from 2004-2013, during which IBM returned more than $140B to shareholders through a combination of dividends and share repurchases. During this time, CEO Sam... View Details
- April 2015 (Revised October 2017)
- Teaching Note
Buffett's Bid for Media General's Newspapers
By: Benjamin C. Esty and Annelena Lobb
On May 12, 2012, BH Media Group, a subsidiary of Warren Buffett's Berkshire Hathaway, announced an offer to buy Media General's (MEG) newspaper division for $142 million in cash and provide debt financing to the struggling firm. Reactions from investors and industry... View Details
Keywords: Mergers ＆ Acquisitions; Bankruptcy; Mergers and Acquisitions; Valuation; Capital Structure; Insolvency and Bankruptcy; Financial Strategy; Risk Management; Executive Compensation; Cash Flow; Business Exit or Shutdown; Media; Advertising; Restructuring; Media and Broadcasting Industry; Publishing Industry; United States
- 2015
- Working Paper
Lost in the Clouds: The Impact of Changing Property Rights on Investment in Cloud Computing Ventures
By: Josh Lerner and Greg Rafert
Our analysis seeks to understand the impact of changing allocations of property rights on investment in new firms. We focus on the Cartoon Network, et al. v. Cablevision decision in the U.S., which narrowed the protection enjoyed by content creators (e.g., movie... View Details
- March 2015 (Revised January 2024)
- Case
CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen (HBS MBA ’01) hoped to win over a prominent venture capital investor for Series B financing of his firm CVI that was creating a drug-eluting balloon (DES) to treat peripheral arterial disease. As a second-mover, Duke felt he was more likely to acquire... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Health Industry; Medical Devices and Supplies Industry; United States; Europe
- March 2015 (Revised September 2016)
- Technical Note
Baidu, Alibaba, and Tencent: The Three Kingdoms of the Chinese Internet
By: Feng Zhu and Aaron Smith
This note provides an overview of the Chinese Internet by describing its leading three companies: Baidu, Alibaba, and Tencent (BAT). While BAT had previously focused their respective businesses on distinct sectors of the online economy—Baidu for search, Alibaba for... View Details
- March 2015
- Case
BOLT: Seed Venture Capital Firm
By: William A. Sahlman and Robert F. White
BOLT is a different kind of seed venture capital firm built to serve the needs of early-stage startups at the intersection of hardware and software.
In the past decade, the cost of entrepreneurial experimentation has dropped dramatically, particularly in web... View Details
In the past decade, the cost of entrepreneurial experimentation has dropped dramatically, particularly in web... View Details
- March 2015
- Article
Signaling to Partially Informed Investors in the Newsvendor Model
By: William Schmidt, Vishal Gaur, Richard Lai and Ananth Raman
We investigate a puzzling phenomenon in which firms make investment decisions that purposefully do not maximize expected profits. Using an extension to the newsvendor model, we focus on a relatively common scenario in which the firm's investor has imperfect information... View Details
- February 2015 (Revised September 2017)
- Supplement
Omar Selim: Building a Values-Based Asset Management Firm (B)
By: George Serafeim, Rebecca Henderson and Shannon Gombos
The case describes the decision of Omar Selim to set up Arabesque as an independent organization and how he organized Arabesque to use both financial and environmental, social and governance (ESG) data in order to deliver performance for its clients. View Details
- February 2015 (Revised June 2017)
- Case
Intrapreneurship at DaVita HealthCare Partners
By: Joseph B. Fuller, David J. Collis and Matthew G. Preble
Josh Golomb, president and general manager of DaVita Rx (Rx), was about to meet with Kent Thiry, CEO of Rx's corporate parent, DaVita Healthcare Partners Inc. (DaVita), in August 2013. The two would discuss whether Golomb should lead a new DaVita venture, Paladina... View Details
- February 2015 (Revised November 2015)
- Supplement
Building an Integrated Biopharma Company: Crucell (B)
By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling
The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8... View Details
Keywords: Biotechnology; Biopharmacy Company; Licensing Agreements In Biopharmacy; Licensing; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Entrepreneurship; Health Care and Treatment; Acquisition; Innovation and Invention; Biotechnology Industry; Pharmaceutical Industry
- February 2015
- Case
Founder Field Day
By: Matthew Rhodes-Kropf, Ramana Nanda and Nathaniel Burbank
Branded as the "Millennial firm for Millennials," Mike Rothenberg founded Rothenberg Ventures (RV) in 2012 while earning his MBA at the Harvard Business School (HBS). Over the following 24 months, Rothenberg raised $20 million and built a venture capital firm that made... View Details
- 2014
- Working Paper
Making the Business Case for Environmental Sustainability
Can a business case be made for acting sustainably? This is a difficult question to answer precisely, largely because there is no generally accepted definition of the term "sustainability". Is it acting sustainably to protect the human rights of the firm's workforce?... View Details
- February 2015 (Revised November 2015)
- Case
Building an Integrated Biopharma Company: Crucell (A)
By: Richard G. Hamermesh, Marianne Van Der Steen and Susan S. Harmeling
By 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space,... View Details
Keywords: Biotechnology; Biopharmacy Company; Licensing; Licensing Agreements In Biopharmacy; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Partners and Partnerships; Entrepreneurship; Growth and Development Strategy; Biotechnology Industry; Pharmaceutical Industry; Netherlands
- February 2015 (Revised June 2016)
- Case
AltSchool: School Reimagined
By: John J-H Kim, Kyla Wilkes and Christine S. An
Max Ventilla and his team launches in 2013 AltSchool, a new network of tech-savvy independent K-8 "micro-schools." AltSchool is born out of Ventilla's frustration with the education options available for his young daughter. During his search, Ventilla comes to the... View Details
Keywords: Education Technology; School Models; Product Development; Entrepreneurship; Talent Development And Retention; Social Impact Investment; Information Technology; Business Model; Education; Business Startups; Customization and Personalization; Growth and Development Strategy; Education Industry; United States
- 2015
- Chapter
Making the Business Case for Environmental Sustainability
Can a business case be made for acting sustainably? This is a difficult question to answer precisely, largely because there is no generally accepted definition of the term "sustainability." Is it acting sustainably to protect the human rights of the firm's workforce?... View Details